Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD…
- Trial name
- SCALA (NCT07725939)
- Testing
- Galvokimig
- Where
- 23 sites in United States, China
- Volunteers
- 402 people
- Sponsor
- UCB Biopharma SRL
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- EMBARK (NCT06883305)
- Testing
- Tezepelumab
- Where
- 305 sites in United States, Brazil and 16 more
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
The primary objective of this study was to compare the long-term (12-week) bronchodilator efficacy and safety of ipratropium bromide / salbutamol combination administered by the Respimat® 40 mcg / 200 mcg (one inhalation q.i.d.)…
- Trial name
- NCT02177253
- Testing
- Ipratropium bromide / Salbutamol, Ipratropium bromide, COMBIVENT Inhalation Aerosol
- Volunteers
- 1,118 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
- Trial name
- NCT02231372
- Testing
- Berodual® Respimat® solution for inhalation
- Volunteers
- 4,602 people
- Sponsor
- Boehringer Ingelheim
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
This study is designed to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder once daily (QD) on arterial stiffness compared with Tiotropium QD over 12 week treatment period in…
- Trial name
- NCT01395888
- Testing
- fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI), Tiotropium
- Where
- 55 sites in Argentina, France and 5 more
- Volunteers
- 260 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease
This is an investigation of the beneficial effects, tolerability and safety of a range of single doses of orally inhaled glycopyrronium bromide (PSX1002GB pMDI) in male and female patients with moderate or severe chronic…
- Trial name
- NCT01703624
- Testing
- glycopyrronium bromide
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Prosonix Limited
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT02119286
- Testing
- FF, VI, UMEC
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 620 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00567996
- Testing
- Indacaterol 150 μg, Salmeterol 50 μg
- Where
- 128 sites in Canada, Colombia and 13 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate or severe COPD…
- Trial name
- NOTUS (NCT04456673)
- Testing
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist
- Where
- 334 sites in United States, Argentina and 27 more
- Volunteers
- 935 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients
Expiratory Flow Limitation (EFL) occurs when the airways become compressed, which usually results when the pressure outside the airway exceeds the pressure inside the airway.
- Trial name
- NCT03851510
- Testing
- Vector ventilator, Resmon Pro
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Philips Respironics
COPD
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease…
- Trial name
- ZION (NCT06496620)
- Testing
- Biological: Solrikitug low dose, Biological: Solrikitug high dose
- Where
- 110 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Uniquity One (UNI)
Chronic Obstructive Pulmonary Disease, COPD
Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease
This purpose of this study is to assess the safety of ramelteon, once daily (QD), in subjects with chronic obstructive pulmonary disease.
- Trial name
- NCT00672802
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Takeda
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Clinical Practice of AECOPD Management in China
The purpose of this study is observe clinical practice including glucocorticoids treatment in AECOPD in China.
- Trial name
- NCT02051166
- Where
- 13 sites in China
- Volunteers
- 5,095 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
This is a multicentre, randomized, blinded, double dummy, parallel group study to evaluate the efficacy and safety of UMEC inhalation powder[ (62.5 microgram (mcg) once daily (QD)] when administered via a novel Dry Powder Inhaler…
- Trial name
- NCT02207829
- Testing
- Umeclidinium, Tiotropium
- Where
- 99 sites in United States, Argentina and 11 more
- Volunteers
- 1,017 people
- Sponsor
- GlaxoSmithKline
Asthma, COPD
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
- Trial name
- POLARIS (NCT00667797)
- Testing
- levalbuterol HCl, albuterol Sulfate
- Where
- 18 sites in United States
- Volunteers
- 486 people
- Sponsor
- Sumitomo Pharma America, Inc.
COPD
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
- Trial name
- NCT07222410
- Testing
- Closed loop oxygen control, Manual titration
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Obstructive Pulmonary Disease
A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
PH-797804 is a potent ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
- Trial name
- NCT00559910
- Testing
- PH-797804
- Where
- 45 sites in Argentina, Australia and 11 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent Exacerbations in Moscow
This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow
- Trial name
- CERERA-MOSCOW (NCT07307781)
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.